{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T21:03:40Z","timestamp":1781211820903,"version":"3.54.1"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100032550","name":"Zydus Lifesciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100032550","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism Open"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.metop.2026.100476","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T15:58:44Z","timestamp":1779292724000},"page":"100476","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Efficacy and safety of novel formulation of semaglutide injection: A multicentre, randomized, comparative, active controlled, phase 3 study in comparison with reference biologic in Indian patients with type 2 diabetes mellitus"],"prefix":"10.1016","volume":"30","author":[{"given":"Prabhat Kumar","family":"Sharma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Viswaprasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Animesh","family":"Choudhary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ansari Rizwanahmed","family":"Nurulhasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sagar Vivek","family":"Redkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patel Manan","family":"Bharatkumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijaykumar Shivajirao","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumit","family":"Anand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijaykumar","family":"Barge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shalin J.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chintan B.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanugula","family":"Sudheer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shrikant","family":"Somani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konatham","family":"Rambabu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surya Veeramani Kartheek","family":"Adhikarla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Swapna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shravan Kumar","family":"Ankathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veer Bahadur","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gouranga","family":"Sarkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.K.","family":"Gautam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalyan Kumar","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaushalendra Nath","family":"Tripathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raja","family":"Bhattacharya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Budithi","family":"Sudarsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deven","family":"Parmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Kansagra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hardik","family":"Pathak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.metop.2026.100476_bib1","unstructured":"International Diabetes Federation. Diabetes facts and figures. Brussels: International Diabetes Federation; n.d. Available from: https:\/\/idf.org\/about-diabetes\/diabetes-facts-figures\/[accessed 31 December 2025]."},{"key":"10.1016\/j.metop.2026.100476_bib2","unstructured":"International Diabetes Federation. India diabetes statistics & health data | IDF diabetes atlas. Brussels: International Diabetes Federation; n.d., https:\/\/diabetesatlas.org\/data-by-location\/country\/india\/[accessed 31 December 2025]."},{"key":"10.1016\/j.metop.2026.100476_bib3","doi-asserted-by":"crossref","first-page":"137","DOI":"10.25259\/NMJI_655_23","article-title":"Lessons learnt from the ICMR\u2013INDIAB study","volume":"36","author":"Mohan","year":"2023","journal-title":"Natl Med J India"},{"key":"10.1016\/j.metop.2026.100476_bib4","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/S2213-8587(23)00119-5","article-title":"Metabolic non-communicable disease health report of India: the ICMR-INDIAB national cross-sectional study (ICMR-INDIAB-17)","volume":"11","author":"Anjana","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.metop.2026.100476_bib5","doi-asserted-by":"crossref","DOI":"10.7189\/jogh.13.04135","article-title":"Prevalence and risk factors associated with undiagnosed diabetes in India: insights from NFHS-5 national survey","volume":"13","author":"Sahadevan","year":"2023","journal-title":"J Glob Health"},{"key":"10.1016\/j.metop.2026.100476_bib6","series-title":"RSSDI clinical practice recommendations 2022","year":"2022"},{"key":"10.1016\/j.metop.2026.100476_bib7","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/dom.15729","article-title":"Clinical efficacy and cost-effectiveness of metformin in different patient populations: a narrative review of real-world evidence","volume":"26","author":"Solini","year":"2024","journal-title":"Diabetes Obes Metabol"},{"issue":"Suppl 1","key":"10.1016\/j.metop.2026.100476_bib8","first-page":"S158","article-title":"Pharmacologic approaches to glycemic treatment: standards of care in diabetes\u20142024","volume":"47","year":"2024","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metop.2026.100476_bib9","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1080\/14740338.2017.1281246","article-title":"Cardiovascular safety and benefits of GLP-1 receptor agonists","volume":"16","author":"Dalsgaard","year":"2017","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.metop.2026.100476_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2025.118266","article-title":"Design, synthesis, and biological evaluation of long-acting glucagon-like peptide-1 conjugates modified with dual fatty acids and a PAS polypeptide","volume":"128","author":"Wang","year":"2025","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.metop.2026.100476_bib11","first-page":"29","volume":"vol. 40","author":"Kommu","year":"2024"},{"key":"10.1016\/j.metop.2026.100476_bib12","doi-asserted-by":"crossref","first-page":"14514","DOI":"10.3390\/cimb46120872","article-title":"Spotlight on the mechanism of action of semaglutide","volume":"46","author":"Papakonstantinou","year":"2024","journal-title":"Curr Issues Mol Biol"},{"key":"10.1016\/j.metop.2026.100476_bib13","unstructured":"Mechanism of action. novoMEDLINK. Available from: https:\/\/www.novomedlink.com\/diabetes\/products\/treatments\/ozempic\/about\/how-ozempic-works.html [accessed 24 May 2026]."},{"key":"10.1016\/j.metop.2026.100476_bib14","first-page":"61","article-title":"Clinical impact of semaglutide, a glucagon-like peptide-1 receptor agonist, on obesity management: a review","volume":"14","author":"Alorfi","year":"2022","journal-title":"Clin Pharmacol"},{"key":"10.1016\/j.metop.2026.100476_bib15","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.diabet.2018.12.001","article-title":"Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in type 2 diabetes: insights from the SUSTAIN 1\u20137 trials","volume":"45","author":"Aroda","year":"2019","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.metop.2026.100476_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2022.996179","article-title":"Gastrointestinal adverse events associated with semaglutide: a pharmacovigilance study based on the FDA adverse event reporting system","volume":"10","author":"Shu","year":"2022","journal-title":"Front Public Health"},{"key":"10.1016\/j.metop.2026.100476_bib17","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/dom.13172","article-title":"Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy","volume":"20","author":"Vilsb\u00f8ll","year":"2018","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.metop.2026.100476_bib18","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41433-021-01741-5","article-title":"Semaglutide and the risk of diabetic retinopathy\u2014current perspective","volume":"36","author":"Sharma","year":"2022","journal-title":"Eye (Lond 1990)"},{"key":"10.1016\/j.metop.2026.100476_bib19","unstructured":"Government of India, Central Drugs Standard Control Organization. Inviting comments on revised guidelines on similar biologics\u2014regulatory. n.d."},{"key":"10.1016\/j.metop.2026.100476_bib20","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S2213-8587(17)30013-X","article-title":"Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1)","volume":"5","author":"Sorli","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.metop.2026.100476_bib21","doi-asserted-by":"crossref","first-page":"765","DOI":"10.2337\/dc20-1473","article-title":"Efficacy and safety of dulaglutide 3.0 mg and 4.5 mg versus 1.5 mg in metformin-treated patients with type 2 diabetes (AWARD-11)","volume":"44","author":"Frias","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metop.2026.100476_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.645617","article-title":"Efficacy of semaglutide in a subcutaneous and an oral formulation","volume":"12","author":"Meier","year":"2021","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.metop.2026.100476_bib23","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2025-005161","article-title":"Long-term comparative effectiveness of once-weekly semaglutide versus alternative treatments in a real-world US adult population with type 2 diabetes","volume":"13","author":"Buse","year":"2025","journal-title":"BMJ Open Diabetes Res Care"},{"key":"10.1016\/j.metop.2026.100476_bib24","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1111\/dom.13353","article-title":"Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events","volume":"20","author":"Ahr\u00e9n","year":"2018","journal-title":"Diabetes Obes Metabol"},{"issue":"Suppl 1","key":"10.1016\/j.metop.2026.100476_bib25","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1210\/jc.2008-1595","article-title":"Obesity and the metabolic syndrome in developing countries","volume":"93","author":"Misra","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metop.2026.100476_bib26","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metop.2026.100476_bib27","article-title":"Safety of semaglutide","volume":"12","author":"Smits","year":"2021","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.metop.2026.100476_bib28","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0140-6736(04)17018-9","article-title":"Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (INTERHEART study)","volume":"364","author":"Yusuf","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.metop.2026.100476_bib29","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/S2213-8587(19)30066-X","article-title":"Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9)","volume":"7","author":"Zinman","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.metop.2026.100476_bib30","doi-asserted-by":"crossref","first-page":"7370","DOI":"10.1021\/acs.jmedchem.5b00726","article-title":"Discovery of the once-weekly glucagon-like peptide-1 analogue semaglutide","volume":"58","author":"Lau","year":"2015","journal-title":"J Med Chem"}],"container-title":["Metabolism Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589936826000356?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589936826000356?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T20:17:38Z","timestamp":1781209058000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589936826000356"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":30,"alternative-id":["S2589936826000356"],"URL":"https:\/\/doi.org\/10.1016\/j.metop.2026.100476","relation":{},"ISSN":["2589-9368"],"issn-type":[{"value":"2589-9368","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of novel formulation of semaglutide injection: A multicentre, randomized, comparative, active controlled, phase 3 study in comparison with reference biologic in Indian patients with type 2 diabetes mellitus","name":"articletitle","label":"Article Title"},{"value":"Metabolism Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metop.2026.100476","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100476"}}